TARS Tarsus Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1819790 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY86.3%
TTM net income YoY-765.3%
TTM EPS YoY-697.0%
Revenue 3-yr CAGR262.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-102.0%
Net margin-102.9%
FCF margin4.8%
EBITDA margin-101.7%
Returns
ROE-319.8%
ROA-135.0%
ROIC (approx.)-330.8%
Asset turnover1.31x
Leverage & solvency
Liabilities / assets79.4%
Debt / equity0.70x
Current ratio1.96x
Interest coverage-80.17x
Cash quality & payout
Operating cash flow / net income-0.07x
Accruals ratio-144.6%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $451.36M | $182.95M |
| R&D expense | $64.32M | $53.39M |
| SG&A expense | $427.32M | $237.31M |
| Operating income | -$70.97M | -$120.57M |
| Interest expense | $8.94M | $7.85M |
| Pretax income | -$64.36M | -$115.55M |
| Income tax | $2.06M | $0 |
| Net income | -$66.42M | -$115.55M |
| EBITDA | -$70.11M | -$119.88M |
| EPS (basic) | -1.59 | -3.07 |
| EPS (diluted) | -1.59 | -3.07 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 41.78M | 37.60M |
| Balance sheet | ||
| Cash & equivalents | $183.64M | $97.38M |
| Short-term investments | $233.63M | $196.56M |
| Receivables | $85.06M | $46.76M |
| Inventory | $4.37M | $2.62M |
| Current assets | $522.78M | $356.70M |
| PP&E, net | $11.66M | $2.31M |
| Intangibles | $7.37M | $8.33M |
| Total assets | $562.16M | $376.99M |
| Current liabilities | $135.69M | $80.61M |
| Long-term debt | $72.44M | $71.84M |
| Total debt | $72.44M | $71.84M |
| Total liabilities | $218.73M | $152.46M |
| Shareholders' equity | $343.43M | $224.53M |
| Net debt | -$111.20M | -$25.54M |
| Shares outstanding | 42.55M | 38.35M |
| Cash flow statement | ||
| Operating cash flow | -$12.45M | -$83.03M |
| Capital expenditure | $9.86M | $1.57M |
| Free cash flow | -$22.31M | -$84.59M |
| Investing cash flow | -$42.12M | -$199.19M |
| Financing cash flow | $143.39M | $154.66M |
| Depreciation & amortization | $855,000 | $685,000 |
| Stock-based compensation | $41.72M | $27.82M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.